Skip to main content

Table 2 Univariate and multivariate analysis of HOXD10 methylation status with 3-year overall survival (OS) in HCC patients

From: Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma

Clinical factor 3-year OS
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age (< 60 vs. ≥ 60 years) 1.306 (0.775–2.201) 0.317   
Gender (male vs. female) 0.717 (0.376–1.368) 0.312   
HOXD10 (methylation vs. unmethylation) 1.920 (1.006–3.664) 0.048* 1.676 (0.864–3.252) 0.127
HBV infection (yes vs. no) 0.664 (0.374–1.178) 0.161   
Liver cirrhosis (yes vs. no) 0.888 (0.513–1.538) 0.672   
Tumor size (≤ 5 vs. > 5 cm) 0.707 (0.412–1.212) 0.207   
Number of lesions (1 vs. ≥ 1) 0.770 (0.439–1.349) 0.361   
Differentiation (well or moderate vs. poor) 0.787 (0.476–1.301) 0.351 1.267 (0.740–2.172) 0.388
TNM stage (stage I + stage II vs. stage III + stage IV) 0.391 (0.233–0.656) 0.000*** 0.502 (0.279–0.902) 0.021*
Lymph node metastasis (negative vs. positive) 0.431 (0.172–1.075) 0.071   
Vessel cancerous embolus (negative vs. positive) 0.356 (0.217–0.584) 0.000*** 0.503 (0.287–0.884) 0.017*
  1. *P < 0.05, ***P < 0.001